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Abstract
Introduction: Breast cancer is the most common female cancer and the second most common
cause of female cancer-related deaths in the United States. World-wide, more than one million
women will be diagnosed with breast cancer annually. In 2007, more than 175,000 women were
diagnosed with breast cancer in the United States. However, deaths due to breast cancer have
decreased in the recent years in part because of improved screening techniques, surgical
interventions, understanding of the pathogenesis of the disease, and utilization of traditional
chemotherapies in a more efficacious manner. One of the more exciting areas of improvement in
the treatment of breast cancer is the entrance of novel therapies now available to oncologists. In
the field of cancer therapeutics, the area of targeted and biologic therapies has been progressing at
a rapid rate, particularly in the treatment of breast cancer.
Since the advent of imatinib for the successful treatment of chronic myelogenous leukemia in the
2001, clinicians have been searching for comparable therapies that could be as efficacious and as
tolerable. In order for targeted therapies to be effective, the agent must be able to inhibit critical
regulatory pathways which promote tumor cell growth and proliferation. The targets must be
identifiable, quantifiable and capable of being interrupted.
In the field of breast cancer, two advances in targeted therapy have led to great strides in the 
understanding and treatment of breast cancer, namely hormonal therapy for estrogen positive 
receptor breast cancer and antibodies directed towards the inhibition of human epidermal growth 
factor receptor (HER)2. These advances have revolutionized the understanding and the treatment 
strategies for breast cancer. Building upon these successes, a host of novel agents are currently 
being investigated and used in clinical trials that will hopefully prove to be as fruitful. This review 
will focus on novel therapies in the field of breast cancer with a focus on metastatic breast cancer 
(MBC) and updates from the recent annual ASCO meeting and contains a summary of the results.
Novel Her-2/EGFR directed therapies
Treatment options for patients with breast cancer were tra-
ditionally based on cytotoxic chemotherapy but now
include therapies directed towards identifiable targets
which sustain tumor proliferation. Often these targeted
therapies are more efficacious and at the same time less
toxic than traditional regimens. The epidermal growth fac-
tor receptor (EGFR) is a transmembrane receptor with
tyrosine kinase activity. The EGFR family includes HER1
(EGFR-1), HER2, HER3, and HER4. Mutations in this
pathway lead to dysregulation in tumor cell proliferation
and differentiation which makes this pathway an attrac-
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tive target for biologic therapies. Led by the success of tras-
tuzumab's HER2 blocking capabilities in breast cancer,
EGFR inhibition with an emphasis on HER2 inhibition
continues to be an area of focus in the treatment of breast
cancer patients. A plethora of new agents directed towards
the EGFR and HER2 pathway have been introduced and
continue to demonstrate promising results.  The results




Lapatinib is an oral small-molecule dual inhibitor of the
tyrosine kinase domain of both epidermal growth factor
receptor (EGFR) and HER2/neu (ErbB-2). It was approved
in March of 2007 for use in patients with advanced, refrac-
tory MBC in conjunction with capecitabine. Its initial test-
ing was in HER2 positive MBC patients who experienced
disease progression while receiving trastuzumab. In a
phase II open-label multi-center study involving HER2
Table 1: Summary of targets, toxicity, and evaluation at ASCO 2008 of novel agents in advanced breast cancer.
Agent Target Toxicity Evaluation at ASCO
Lapatinib EGFR/HER2 Diarrhea, rash, nausea, vomiting -monotherapy in inflammatory BC
-c/w trastuzumab
-c/w bevacizumab
HKI-272 Pan HER Diarrhea, nausea n/a
Trastuzumab DM-1 HER2 Transaminitis, fatigue, thrombocytopenia, anemia, 
neuropathy
-monotherapy refractory to trastuzumab
Pertuzumab HER2 Diarrhea, pain, nausea, vomiting, mucositis -c/w trastuzumab
Tanespimycin HSP 90 Fatigue, diarrhea, dizziness, headache -c/w trastuzumab
Cetuximab EGFR Rash, diarrhea, nausea, vomiting -c/w carboplatin in triple negative BC
-c/w irinotecan





Gefitinib EFGR Rash, diarrhea, nausea, vomiting -c/w anastrazole
RAD001 mTOR Stomatitis, fatigue, anorexia, diarrhea, headache, rash -c/w anastrazole
-c/w paclitaxel and trastuzumab
-c/w navelbine and trastuzumab
Pazopanib VEGFR, PDGFR, C-kit Diarrhea, rash, nausea -c/w lapatinib
Sunitinib VEGFR, PDGFR, C-kit Mucositis, fatigue, nausea, diarrhea n/a
Axitinib VEGFR 1,2, PDGFR, C-kit Diarrhea, nausea, alopecia, stomatitis n/a
C1311 Topoisomerase II Neutropenia -monotherapy in refractory BC
Pemetrexed Anti-folate Myelosuppression, anemia -1st line monotherapy in advanced BC
Larotaxel Cytotoxic Neutropenia, fatigue -c/w trastuzumab
Orataxel Cytotoxic Neutropenia, fatigue, peripheral neuropathy -monotherapy in taxane resistant BC
Abbreviations: ASCO; American Society of Clinical Oncology; EGFR, epidermal growth factor receptor; HER, human epidermal receptor; BC, 
breast cancer; c/w, combination with; n/a, not applicable; HSP, heat shock protein; VEGF, vascular endothelial growth factor; mTOR, mammalian 
target of rapamycin; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptorJournal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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positive MBC patients refractory to trastuzumab, 80
patients were treated with lapatinib monotherapy at 1500
mg daily.[2] The overall response rate (ORR) was 8%,
14% of patients achieved stable disease and 22% of
patients were free of progression. Adverse events with lap-
atinib were tolerable with anorexia, nausea, rash, vomit-
ing, diarrhea, and weight loss being the most common
events. Cardiotoxicity was not significantly observed. A
second phase II study confirmed lapatinib's activity in
HER2 positive MBC patients in the first-line setting.[3] In
this study, 60 patients were randomized to either lapat-
inib 1500 mg daily or 500 mg twice daily. The ORR was
similar in both groups: 28% in the 1500 mg daily group
and 29% in the 500 mg twice daily group. There were no
grade 3 or 4 adverse events. These two phase II studies led
the way for lapatinib to be investigated in further clinical
trials.
At ASCO 2008, lapatinib monotherapy was evaluated in
patients with HER2 positive relapsed/refractory inflam-
matory breast cancer.[4] In this study, 126 HER2 positive
patients with inflammatory breast cancer refractory to
anthracyclines, taxanes, and traztuzumab were treated
with continuous lapatinib monotherapy at 1500 mg
daily. Preliminary data demonstrated an estimated ORR
of 40%. The most frequent toxicities were diarrhea and
skin rash. It was concluded that lapatinib montherapy is
active in the treatment of relapsed/refractoryy HER2 posi-
tive inflammatory breast cancer where currently only a
few effective therapies are available.
Lapatinib has also been successfully combined with
chemotherapy in breast cancer patients. In an open-label
study, patients with HER2 positive locally advanced and
MBC who experienced disease progression after treatment
with regimens that included an anthracycline, a taxane,
and trastuzumab were randomly assigned to receive either
combination lapatinib 1250 mg daily plus capecitabine
2000 mg daily or capecitabine 2500 mg daily alone.[5]
The median time to progression (TTP) was 8.4 months in
the combination group as compared with 4.4 months in
the capecitabine monotherapy group. This improvement
was achieved without an increase in serious grade 3/4
events. Again, cardiotoxicity was not a significant event.
This trial led to its first approval for use in MBC patients.
Lapatinib was further tested in combination therapy when
it was evaluated in conjuction with taxanes. In a phase III
randomized double-blind study of 580 patients, lapatinib
1500 mg daily combined with paclitaxel 175 mg/m2 was
compared with paclitaxel 175 mg/m2 alone as first-line
treatment for patients with MBC irrespective of HER2 sta-
tus.[6] The ORR was 35% vs 25% in favor of the com-
bined group. However, TTP and overall survival (OS) were
not significantly different between the two arms except in
a subgroup of patients with HER2 positive advanced
breast cancer. As expected, there was a significantly greater
toxicity profile in the combination group over the paclit-
axel monotherapy group with alopecia, nausea, vomiting,
rash and diarrhea being the most common events.
A highly anticipated study was presented at ASCO 2008
involving heavily pretreated HER2 positive MBC patients
progressing on trastuzumab therapy who were treated
with lapatinib alone or in combination with trastuzu-
mab.[7] In the study, 296 patients who were previously
treated and suffered disease progression on trastuzumab
therapy were randomized to either lapatinib 1000 mg
daily plus trastuzumab 2 mg/kg weekly or lapatinib 1500
mg daily alone. The combination group achieved a signif-
icant improvement in progression free survival (PFS) (12
weeks vs 8.4 weeks) and clinical benefit rate (CBR)
(25.2% vs 13.2%). However the differences in OS and
ORR were not statistically significant. Both treatments
were well tolerated with an asymptomatic decline in LVEF
occurring in 5% of the patients in the combination arm
and in 2% of the patients in the lapatinib monotherapy
arm. This was the largest study using the combination of
these two agents and the first to show synergy of the
agents in a randomized setting.
At ASCO 2008, lapatinib was also combined with bevaci-
zumab in a phase II single arm study evaluating 31
patients with heavily pretreated HER2 positive MBC.[8]
Lapatinib was administered at a dose of 1500 mg daily
and bevacizumab was administered at 10 mg/kg iv q 2
weeks. The study revealed that at 12 weeks PFS rate was
62%, and at 24 weeks the CBR was 56%. The combination
of these two agents was tolerable with the most com-
monly reported adverse events being diarrhea, muscle
pain, fatigue, nausea and vomiting. The trial continues to
accrue, and updated results are pending. The implications
for this combination are attractive in that the study
showed promising activity in this group of patients with-
out the increased cardiotoxicity that is faced when bevaci-
zumab is combined with trastuzumab.
HKI-272
HKI-272 is an irreversible orally active pan-HER receptor
tyrosine kinase inhibitor with potential anti-neoplastic
activity. It binds to the HER2 receptor irreversibly thus
reducing autophosphorylation in cells by targeting a
cysteine residue in the ATP-binding pocket of the receptor
which ultimately decreases tumor cell proliferation.[9] It
is highly active against HER2 overexpressing human
breast cancer cell lines in vitro.[9] It also inhibits the EGFR
kinase and proliferation of EGFR-dependent cells.[9] It
has been evaluated in a phase II study involving advanced
HER2 positive breast cancer patients.[10] In this open
label phase 2 study, 49 advanced HER2 positive breastJournal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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cancer patients were divided into two treatment arms. The
first arm included HER2 positive breast cancer patients
who were previously treated with trastuzumab and the
second arm included advanced HER2 positive breast can-
cer patients with no prior trastuzumab treatment. Tumor
response and progression-free survival data continues to
be gathered, but out of 32 evaluable patients, 6 patients
achieved a confirmed partial response with additional
patients achieving an unconfirmed partial response.
Diarrhea and nausea were the major adverse effects noted
in the study. Early preliminary data shows that daily
administration is generally tolerable and has antitumor
activity in patients with HER2 positive advanced breast
cancer.
A phase I/II of HKI-272 in combination with trastuzumab
in patients with advanced breast cancer has currently
reached accrual and is awaiting data analysis.[11] It is also
currently being evaluated in phase I/II studies in combina-
tion with paclitaxel as well as in combination with vinor-
elbine in patients with advanced breast cancer.[11] These
investigations appear promising and may allow for fur-




Trastuzumab DM-1 is a first in-class HER2 antibody drug
conjugate which is designed to increase the potency anti-
body-directed therapy. Trastuzumab is combined with
DM-1, a highly potent anti-microtubule agent derived
from the fungal toxin maytansine.[12] At ASCO 2008,
two phase I studies were presented for its use in HER2 pos-
itive advanced MBC. In the first study, 24 patients with
HER2 positive MBC who had progressed on trastuzumab
therapy received 156 doses of trastuzumab DM-1 at six
different dose levels including 0.3 mg/kg, 0.6 mg/kg, 1.2
mg/kg, 2.4 mg/kg, 3.6 mg/kg and 4.8 mg/kg administered
IV q 3 weeks.[13] 6 of 16 patients given doses at 2.4 mg/
kg and 3.6 mg/kg achieved a PR and 5 additional patients
achieved stable disease ongoing after 130 to 260 days.
Adverse events included transaminase elevations, throm-
bocytopenia, fatigue, anemia and neuropathy. Cardiac
toxicity was not observed. It was concluded that the max-
imal tolerated dose and recommended dose for phase II
trials should be 3.6 mg/kg IV q 3 weeks as it is a tolerable
and manageable dosing schedule. In the second phase I
study, trastuzumab DM-1 was administered to HER2 pos-
itive MBC who had progressed on trastuzumab therapy
given IV on a weekly basis in a dose-escalated fashion.[14]
7 patients were given trastuzumab DM-1 weekly at three
different dose levels including 1.2 mg/kg, 1.6 mg/kg and
2.0 mg/kg and at the time of the presentation 4 patients
achieved an unconfirmed PR. Adverse events included
thrombocytopenia, fatigue, transaminase elevations, and
headache. Again, cardiotoxicity was not observed. It was
concluded that high-grade toxicities were minimal and
dose escalation will continue until a maximal tolerated
dose is achieved. These initial studies will hopefully be the
spring board for launching this promising agent for treat-
ment of trastuzumab resistant MBC patients.
Pertuzumab
Pertuzumab is a humanized monoclonal antibody that
binds to the specific dimerization epitope of HER2 steri-
cally blocking heterodimerization of HER2 thereby inhib-
iting intracellular signaling. Initial phase II studies of
pertuzumab in MBC patients showed that pertuzumab
was safe and well tolerated but had limited efficacy in this
group of patients.[15] At ASCO 2008, an update on a
phase II single-arm study of trastuzumab at 2 mg/kg q
week or 6 mg/kg q 3 weeks combined with pertuzumab
420 mg q 3 weeks in patients with HER2 positive MBC
who progressed during trastuzumab therapy was pre-
sented.[16] Initial results showed that out of 33 evaluable
patients, an ORR was seen in 6 patients with one person
achieving a CR and 5 patients achieving a PR. Further-
more, 7 patients achieved stable disease after 6 months,
and 10 patients achieved stable disease in less than 6
months. The adverse effects of this combination included
diarrhea, pain, nausea, vomiting and mucositis. This
study suggests potential anti-tumor activity of pertuzu-
mab in combination with trastuzumab in patients who
are refractory to trastuzumab. The combination was well




Heat shock protein 90 (Hsp9) is a molecular chaperone
for various signaling proteins that promote cancer prolif-
eration and resistance. Tanespimycin (17-AAG) is an
ansamycin antibiotic that binds to Hsp90 and induces the
degradation of proteins that require this chaperone
thereby inducing tumor cell regression. Initial studies
showed that this agent reduced ErbB2 levels and inhibited
proliferation of trastuzumab resistant breast tumor
cells.[17] This made it a potential agent in trastuzumab
resistant HER2 positive patients. At 2008 ASCO, a trial
combined tanespimycin 450 mg/m2 weekly and trastuzu-
mab at standard dose in HER2 positive MBC refractory to
trastuzumab therapy.[18] Of the 21 evaluable patients the
ORR was found to be 24%, and the CBR was found to be
57%. 5 patients achieved a confirmed PR, 5 patients
achieved stable disease, and 2 patients had a measurable
response with a decrease in tumor markers. Toxicities that
are common to cytotoxic chemotherapies such as alo-
pecia, myelosuppression and neuropathy were not
observed. The most predominant side effects were fatigue,
diarrhea, dizziness and headache. It was concluded thatJournal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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the combination of tanespimycin and trastuzumab was
active in HER2 positive MBC who progressed on trastuzu-
mab based therapies with a relatively safe toxicity profile.
These results suggest further investigation of tanespimycin
in the treatment of HER2 over-expressed MBC patients.
EGFR inhibitors
Cetuximab
Cetuximab is a human-mouse chimeric monoclonal anti-
body that competitively binds to EGFR to inhibit dimeri-
zation. It is currently approved for the treatment of both
colorectal cancer and head and neck cancer. Its use in
breast cancer has been evaluated in a phase II study of
weekly irinotecan and carboplatinum with or without
cetuximab in patients with MBC.[19] ORR was signifi-
cantly improved with the addition of cetuximab than with
irinotecan and carboplatinum alone (39% vs 19%). As
expected the toxicity in the triple drug therapy group was
increased but tolerable.
At ASCO 2008, an update of the TBCRC 001 trial was pre-
sented.[20] In this phase II multi-center randomized
study in patients with metastatic triple negative (basal-
like) breast cancer, 102 patients were randomized to
either carboplatin AUC 2 plus cetuximab 250 mg/m2
weekly or carboplatin alone. The results revealed that in
patients included in the carboplatin monotherapy arm
6% achieved a PR, 4% achieved stable disease, and the
clinical benefit rate was 10%. In the combination arm, the
ORR was 18%, 9% of patients had stable disease, and the
clinical benefit rate was 27%. Although most patients pro-
gressed rapidly owing to the aggressive nature of the dis-
ease, it was concluded that single agent carboplatin had
minimal activity in this type of MBC while the combina-
tion of carboplatin and cetuximab did show significantly
improved anti-tumor activity.
Also presented at ASCO 2008 was a trial of cetuximab in
combination with irinotecan in a phase II study in
patients with MBC previously treated with an anthracy-
cline or a taxane-based therapy.[21] In this study, 19
patients were treated with cetuximab 250 mg/m2 weekly
and irinotecan 80 mg/m2, and the results showed that the
ORR was 11% with one patient achieving a PR and 1
patient achieving a CR. One patient had stable disease for
11 cycles. The toxicity profile was well tolerated with der-
matologic toxicities being the most common. It was con-
cluded that although the combination therapy was well
tolerated, the combination had minimal activity in this
group of pretreated patients.
Anti-angiogenesis agents
The vascular endothelial growth factor family of glycopro-
teins are ligands for receptor tyrosine kinases for which
when overexpressed are thought to be essential for tumor
growth and angiogenesis. Angiogenesis is necessary for
cancer growth, invasion and metastasis. Several therapeu-
tic agents have been developed which target this pathway
and have already been incorporated into standard treat-
ment regimens for numerous solid organ cancers. Breast
cancer continues to be an area of interest for the use of
these agents particularly in the metastatic setting.
Bevacizumab
Bevacizumab is a humanized monoclonal antibody
which inhibits all isoforms of vascular endothelial growth
factor (VEGF). It has proven to have activity in combina-
tion with other chemotherapies in the treatment of several
malignancies including lung, colorectal, renal and breast
cancer. It initially gained attention for the treatment of
breast cancer in a phase I/II dose escalation study of
patients with MBC who had progressed on previous ther-
apy.[22] In this study, 75 patients were treated with beva-
cizumab at a dose of 3 mg/kg, 10 mg/kg or 20 mg/kg in a
bi-weekly basis. The ORR ranged from 6.7–17% in all
patients. In the group of patients that were treated with 10
mg/kg, the ORR was 12%. This led the way for bevacizu-
mab to be evaluated in further studies for the treatment of
breast cancer.
Bevacizumab has been evaluated in combination with
chemotherapies known to be efficacious in MBC. In a
phase III randomized clinical trial of chemo-naive MBC
patients coordinated by the Eastern Cooperative Oncol-
ogy Group (ECOG) E2100, paclitaxel 90 mg/m2 in com-
bination with bevacizumab 10 mg/kg was compared to
paclitaxel alone.[23] The patients in the combination arm
achieved a significantly longer PFS compared to the pacl-
itaxel monotherapy arm (11.4 months vs 6.11 months)
and a significantly increased ORR (30% vs 14%). How-
ever, the study failed to show a significant difference in
OS. In a randomized phase III trial, bevacizumab was
combined with capecitabine and compared to capecitab-
ine alone in patients with previously treated MBC.[24]
The study revealed that the combination group achieved a
significantly greater ORR when compared with the
capecitabine monotherapy group (19.8% vs 9.1%), but it
failed to show a significant difference in OS or PFS.
At ASCO 2008, bevacizumab was further evaluated in
combination therapy. In addition to the previous study
involving combination therapy with lapatinib[8], bevaci-
zumab was assessed in combination with docetaxel in a
phase III randomized double blind placebo controlled
study in locally recurrent or MBC referred to as the
AVADO trial.[25] 736 patients from 24 different countries
were treated with the combination of bevacizumab at
high (15 mg/kg) and low dose (7.5 mg/kg) plus docetaxel
100 mg/m2 or docetaxel alone, and the results showed
that PFS was statistically significantly superior for bothJournal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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bevacizumab containing arms compared to the docetaxel
alone arm with a hazard ratio of 0.69 in the low-dose bev-
acizumab arm and 0.61 in the high-dose bevacizumab
arm. ORR was also superior in both combination arms
(55% in the low dose bevacizumab arm and 63% in the
high dose bevacizumab arm) relative to docetaxel alone
(44%). As the data was too immature at the time of the
presentation, OS could not be assessed. Adverse events
were increased in a limited fashion in both combination
arms when compared to placebo, but the combination of
docetaxel and bevacizumab did not reveal any new safety
concerns.
At ASCO 2008, bevacizumab was also evaluated in com-
bination with nab-paclitaxel for MBC patients in the first-
line setting.[26] In this multi-center, open-label phase II
study, 41 patients were treated with weekly nab-paclitaxel
125 mg/m2 in combination with bevacizumab 10 mg/kg
as first-line therapy, and the results demonstrated an ORR
of 30%. Stable disease at > 16 weeks was achieved in 22%
of patients, and the median PFS was 9.2 months. The
most common adverse events were neutropenia, anemia
and peripheral neuropathy. It was concluded that the
combination of nab-paclitaxel and bevacizumab is a tol-
erable combination with potential activity in MBC
patients in the first-line setting.
Other studies presented at ASCO 2008 evaluated bevaci-
zumab's safety and feasibility in combination with several
current first-line therapies. In an ECOG coordinated trial
labeled E2104, bevacizumab was evaluated in a phase II
feasibility trial incorporating it into dose-dense doxoru-
bicin and cyclophosphamide (AC) followed by paclitaxel
(T) in patients with lymph-node positive breast can-
cer.[24] The primary endpoint was the incidence of clini-
cally apparent cardiac dysfunction, and preliminary data
suggests that the incorporation of bevacizumab into dose
dense AC→T is a feasible and promising combination.
A second multi-center phase II double-blind randomized
trial investigated the safety of bevacizumab at 7.5 mg/kg
and 15 mg/kg in combination with docetaxel, doxoru-
bicin and cyclophosphamide (TAC) for patients with
stage II or III breast cancer in the neoadjuvant setting.[27]
Of the 37 evaluable post surgical patients, the ORR was
95% including 59% of patients achieving a clinical CR
and 35% of patients achieving a clinical PR. Data is cur-
rently being compiled and evaluated to detect a difference
between patients that received and did not receive bevaci-
zumab, but the preliminary data for this combination
shows potential.
Stemming from the success of bevacizumab in combina-
tion with paclitaxel in E2001, a large, open-label single-
arm study was presented which would analyze the safety
and tolerability of bevacizumab in combination with tax-
ane-based therapy for patients with locally recurrent or
MBC.[28] This study will attempt to further elucidate the
safety profile of bevacizumab with taxane-based therapy
in a broader patient population by including patients in
the community setting with plans to accrue more than
2,300 patients from 50 countries. The studies presented at
ASCO 2008 will hopefully be the initial stages of incorpo-
rating bevacizumab into current standards of care for
patients with breast cancer.
Also presented at ASCO 2008 was a retrospective study
that evaluated bevacizumab's tolerance in the elderly
patient population.[29] The study examined the medical
record of patients above the age of 60 with MBC who were
treated with bevacizumab combination therapy. The
study suggested that these older patients had more grade
3/4 thrombosis, bleeding, perforation, fatigue and febrile
neutropenia than patients in historical randomized phase
III trials of bevacizumab plus chemotherapy. It was con-
cluded that the risks and benefits of bevacizumab therapy
must be weighed prior to its use in the elderly population.
Hormonal-resistance reversing agents
The majority of breast cancers in post menopausal women
express estrogen and/or progesterone receptors. This sub-
group of breast cancers carries a better prognosis than
estrogen/progesterone receptor negative patients, and
they can often be treated with hormonal therapy alone.
However hormone resistance ultimately becomes a major
treatment barrier and, cytotoxic chemotherapy becomes a
necessity. There is evidence that estrogen receptor positive
breast cancers become resistant to hormonal therapy by
up-regulating other signaling pathways involved in tumor
proliferation such as EGFR, HER2, MAPK and PI3K/Akt.
[30-32] Novel strategies have now been employed to over-
come this resistance by the addition of new signal trans-
duction inhibiting agents to standard hormonal agents.
Gefitinib
Gefitinib is an orally-active small molecule selective EGFR
tyrosine kinase inhibitor. Its use as monotherapy in
advanced and refractory MBC has proven to be disap-
pointing as demonstrated by two early phase II clinical tri-
als for which it was found to have little anti-tumor activity
in breast cancer.[33,34] However, its activity in combina-
tion therapy has shown more potential. It has been evalu-
ated in combination therapy in two phase II studies for
which it was combined with docetaxel in the first-line set-
ting. In the first study, 41 patients received oral gefitinib
250 mg per day along with docetaxel at 75 mg/m2 and
100 mg/m2.[35] There was no difference in activity or tol-
erability between the two docetaxel doses. The ORR was
54% with a complete response (CR) and partial responseJournal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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(PR) in 22 out of 41 patients. Toxicities included neutro-
penia, diarrhea, rash and anemia.
The second study was a phase II multi-institutional trial to
determine the efficacy and tolerability of gefitinib 250 mg
daily and docetaxel 75 mg/m2 as first-line treatment in
patients with MBC presented at ASCO 2007.[36] 33
patients with MBC received the combination of gefitinib
and docetaxel, and the results demonstrated a CBR of 51%
and an ORR of 39.4%. Most toxicities were attributed to
docetaxel rather than gefitinib. It was concluded that the
combination of docetaxel and gefitinib was an active reg-
imen in MBC, and the toxicities and efficacy were similar
to those of docetaxel alone. Unfortunately, gefitinib's
activity in MBC could not be elucidated in these two
phase II studies as the trials did not include a docetaxel
alone group for comparison.
At ASCO 2008, gefitinib was evaluated in combination
with anastrozole in a phase II multicenter, double blind,
randomized trial to investigate its efficacy on reversing
resistance to hormone therapy.[37] In this trial, 94
women with newly diagnosed hormone receptor positive
MBC were randomized to receive anastrozole 1 mg daily
in combination with either gefitinib 250 mg daily or pla-
cebo with the primary end point of the study being PFS.
The results of the study showed a superior PFS in the gefit-
inib group when compared with placebo (14.5 months vs
8.2 months). The CBR also favored the gefitinib group
when compared with placebo (49% vs 34%). The treat-
ment-related adverse events were generally mild and well
tolerated but were seen twice as often in the gefitinib arm
when compared with the placebo arm. It was concluded
that the combination of anastrazole plus gefitinib is well
tolerated and shows increased anti-tumor activity when
compared to anastrazole alone in this group of MBC
patients. These results are promising and demands further
study of this combination in MBC patients.
RAD001
RAD001 is a highly specific inhibitor of the mammalian
target of rapamycin (mTOR), a large polypeptide kinase
which forms part of the PI3K/Akt pathway. This pathway
is a central regulator of intracellular signaling pathways
involved in tumor cell growth, proliferation and angio-
genesis.[38,39] Its use is currently gaining attention in the
treatment of several genitourinary malignancies, but its
use in breast cancer has also been investigated. A phase I
study investigated the safety and pharmacokinetics of
combined treatment with letrozole 2.5 mg per day and
RAD001 at at 5 mg or 10 mg per day in patients with MBC
stable or progressing after > or = 4 months on letrozole
alone.[40] Seven patients received the combination ther-
apy for > 6 months. One patient had a complete response,
and one had a 28% reduction in liver metastases, both in
the high dose RAD001 group. The most common adverse
events were stomatitis, fatigue, anorexia and/or decreased
appetite, diarrhea, headache and rash. There was no clini-
cally relevant pharmacokinetic interaction detected
between the two agents. It was concluded that therapy
with RAD001 plus letrozole is promising with the overall
safety profile of the combination consistent with that
expected for RAD001 monotherapy.
This study led the way to a study presented at ASCO 2008
for which RAD001 was investigated in combination with
letrozole in a randomized phase II trial in ER positive
breast cancer patients in the neoadjuvant setting.[41] 270
post-menopausal women with ER positive tumors were
randomized to letrozole 2.5 mg daily plus RAD001 10 mg
daily or letrozole plus placebo. The clinical response rate
favored the combination of letrozole plus RAD001 arm
over the letrozole plus placebo arm (68% vs 59%). How-
ever, the rate of high grade toxicity was more frequent in
the combination group when compared with placebo
(22.6% vs 3.8%). The most common adverse events were
hyperglycemia, stomatitis, interstitial lung disease and
infections. It was concluded that RAD001 significantly
increases the efficacy of letrozole in newly diagnosed ER
positive breast cancer.
At 2008 ASCO, RAD001 was also evaluated in a phase I
study where it was combined with weekly paclitaxel 80
mg/m2 and trastuzumab 2 mg/kg weekly in patients with
HER2 positive MBC with prior resistance to trastuzu-
mab.[42] At the time of the presentation, 13 heavily pre-
treated patients were enrolled and treated with paclitaxel
and trastuzumab with the addition of RAD001 given in a
daily or weekly basis. All 3 patients in the daily arm
achieved a PR. Of the 4 patients in the weekly arm, 2
patients achieved a PR, 1 patient achieved a minor regres-
sion, and 1 patient achieved stable disease. The most com-
mon adverse events were neutropenia and stomatitis. The
combination was well tolerated and showed probable
activity in this group of heavily pretreated patients.
In a second phase I study presented at ASCO 2008,
RAD001 was combined with vinorelbine and trastuzu-
mab in a similar group of patients.[43] In this study,
vinorelbine 25 mg/m2 and trastuzumab 2 mg/kg weekly
was combined with RAD001 given in a weekly or daily
fashion and administered to 19 heavily pretreated HER2
positive patients who had progressed on trastuzumab
therapy. Of the 8 evaluable patients in the daily arm, 2
patients achieved a PR, and 4 patients achieved SD. Toxic-
ities included stomatitis and neutropenia. Of the 9 evalu-
able patients in the weekly arm, 1 patient achieved a PR
and 7 patients achieved stable disease. Neutropenia was
the most common adverse event reported in this group of
patients. It was concluded that RAD001 is well toleratedJournal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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in combination with vinorelbine and trastuzumab and
shows potential anti-tumor activity in heavily pretreated





Pazopanib is an oral, multi-targeted inhibitor targeting all
isoforms of VEGFR, platelet-derived growth factor recep-
tor (PDGFR) and c-kit. It has already shown to be effica-
cious in renal cell cancer (RCC) in a phase II randomized
discontinuation trial in 225 patients with metastatic
RCC.[44] At ASCO 2008, a randomized study compared
pazopanib 400 mg daily plus lapatinib 1000 mg daily to
lapatinib 1500 mg daily alone in patients with untreated
HER2 positive advanced or MBC in the first-line set-
ting.[45] The progressive disease rate was higher in the
lapatinib alone group when compared to the combina-
tion group (27% vs 19%). The ORR also favored the com-
bination group (44%) when compared to the lapatinib
monotherapy group (30%). The most common adverse
effects in the combination group were diarrhea, rash and
nausea. Liver function abnormalities were also more com-
mon in the combination group. This was the first phase II
trial to evaluate the combination of two oral targeted
agents in first-line HER2 positive MBC patients.
Sunitinib
Sunitinib is an orally-active small molecule tyrosine
kinase inhibitor that acts on multiple targets including
VEGFR, PDGFR, c-kit and Flt-3.[46] In a phase II, open-
label, multicenter study, sunitinib was evaluated as mon-
otherapy in patients with MBC. 64 patients previously
treated with an anthracycline and a taxane received
sunitinib 50 mg daily in six week cycles, and results
showed that 7 patients achieved a partial response with a
median duration of 19 weeks giving an ORR of 11%. 3
patients achieved stable disease for greater than 6 months.
The median TTP was 10 weeks, and the OS was 38 weeks.
The most common adverse events were fatigue, nausea,
diarrhea, mucosal inflammation and anorexia, but most
were mild to moderate and effectively managed.
These promising results have led to many ongoing clinical
trials using sunitinib in the metastatic setting. One trial
will evaluate the combination of sunitinib with docetaxel
in patients with MBC).[47] A second trial will evaluate
sunitinib in combination with docetaxel and traztuzumab
in advanced HER2 positive MBC patients).[47] Lastly,
There is a neoadjuvant study using sunitinib, approved by
NCI and will be open for accrual shortly through SWOG.
This trial is designed as a phase II study using weekly nan-
oparticle albumin bound paclitaxel (nab-paclitaxel), with
or without sunitinib followed or preceded by weekly dox-
orubicin and daily cyclophosphamide as neoadjuvant
therapy for inflammatory and locally advanced Her-2/
Neu negative breast cancer. These upcoming trials may
lead to the incorporation of sunitinib in future regimens
in not only the metastatic setting but also the neoadjuvant
setting as well.
Axitinib
Axitinib (AG013736) is an orally active multi-kinase
inhibitor that inhibits the receptor tyrosine kinases
VEGFR 1 and 2, PDGFR and c-KIT. Its activity in breast
cancer was demonstrated at ASCO 2007 in a randomized
double blind phase II study of axitinib 5 mg twice daily in
combination with docetaxel 80 mg/m2 or placebo.[48]
168 previously untreated patients with MBC were rand-
omized in this study, and the results showed a significant
ORR in favor of the axitinib group when compared to pla-
cebo (40% vs 23%). In addition, TTP favored the axitinib
group when compared to placebo (9 months vs 6.3
months). The most common adverse events in the combi-
nation arm were diarrhea, nausea, alopecia, fatigue and
stomatitis. It was concluded that the combination of
axitinib and docetaxel is tolerable and has potential anti-
tumor activity for MBC in the first-line setting. Further
studies using axitinib in breast cancer are ongoing.
Topoisomerase II inhibitors
C1311
C1311 is an inhibitor of topoisomerase II whose design
was based upon mitoxantrone but with less cardiotoxicity.
At 2008 ASCO, a phase II trial including 53 MBC patients
resistant to taxanes, anthracyclines, multiple hormonal
therapies and other cytotoxic agents were treated with
C1311 480 mg/m2 weekly.[49] The ORR was found to be
40% with 36% of patients achieving stable disease. The
main toxicity was neutropenia, and cardiac toxicity was
minimal. It was concluded that C1311 shows activity in
pretreated MBC with some disease control and a manage-




Bisphosphonate use in breast cancer was also examined in
several studies at ASCO 2008. Zoledronic acid has dem-
onstrated anti-tumor and anti-metastatic activity in pre-
clinical models, and it was investigated in an ABCSG-12
study evaluating adjuvant ovarian suppression combined
with tamoxifen or anastrozole alone or in combination
with zoledronic acid in premenopausal women with
endocrine-responsive stage I and II breast cancer.[50]
1,801 premenopausal women with endocrine-responsive
breast cancer were administered either goserelin 3.6 mg q
28 days and tamoxifen 20 mg daily with or without
zoledronic acid 4 mg iv q 6 months or goserelin and anas-Journal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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trazole 1 mg daily with or without zoledronic acid for a
period of three years. There was no significant difference
in results for patients who received tamoxifen or anastra-
zole alone, but anti-hormonal therapy with zoledronic
acid increased disease free survival by 36% and relapse-
free survival by 35% compared to anti-hormonal therapy
alone. The difference in OS was not significant but
trended in favor of the zoledronic acid arms. It was con-
cluded that adjuvant zoledronic acid improves outcomes
in endocrine responsive patients further than anti-hormo-
nal therapy alone.
A second study evaluated the effects of zoledronic acid on
bone mineral density comparing upfront versus delayed
treatment in an open-label trial in postmenopausal
women with primary breast cancer starting letrozole after
tamoxifen.[51] 558 women without osteoporosis were
treated with zoledronic acid 4 mg q 6 months either in an
upfront or a delayed fashion, and the results demon-
strated that patients in the upfront arm averaged a 3.7%
increase in lumbar spine bone mineral density while the
delayed arm averaged a 1.7% decrease in bone mineral
density. The rates of clinically meaningful decline in lum-
bar spine bone mineral density also favored the upfront
arm when compared to the delayed arm (3% vs 20.7%). It
was concluded that upfront use of zoledronic acid signifi-
cantly prevented bone loss when compared to delayed
therapy in postmenopausal patients without osteoporosis
starting letrozole following tamoxifen for primary breast
cancer.
Ibandronate
Ibandronate is another bisphosphonate that was evalu-
ated at ASCO 2008. In a double blind, randomized, pla-
cebo controlled trial labeled the ARIBON trial, the effect
of ibandronate on bone mineral density was assessed.[52]
131 post menopausal women were categorized into three
groups: women with normal bone density, women with
osteopenia, and women with osteoporosis. All patients
were treated with anastrozole 1 mg daily, calcium and
vitamin D. The patients in the osteopenic group were ran-
domized in a 1:1 fashion to either ibandronate or pla-
cebo. The patients in the osteoporosis group all received
ibandronate 150 mg monthly. The patients in the osteo-
penia group who received ibandronate achieved a mean
difference in percentage bone mineral density changes of
6.2% at the lumbar spine and 4.5% at the hip after 2 years
of therapy when compared to placebo. Improvement in
bone mineral density was also observed in the group of
patients with osteoporosis when treated with ibandro-
nate. It was concluded that oral ibandronate prevents
anastrozole-induced bone loss and results in significant
increases in bone mineral densities at the lumbar spine
and the hip in this group of osteopenic and osteoporotic
patients.
These studies not only reinforce the necessity of bisphos-
phonate therapy in patients receiving endocrine therapy
for the prevention of bone loss, but they also illustrate the
powerful anti-tumor activity of these agents as well.
Novel chemotherapies
Pemetrexed
Pemetrexed is a multi-targeted anti-folate that inhibits
several enzymes in the de novo synthesis of purines and
pyrimidines. Several studies have examined its efficacy in
MBC beginning with a phase II study in patients with
locally recurrent or MBC. In this study, 38 MBC patients
were treated with pemetrexed 600 mg/m2, and the ORR
was 28% with one patient achieving a CR and 9 patients
achieving a PR. Median duration of response was 9
months and median OS was 13 months. Toxicities
included neutropenia and thrombocytopenia.[53] This
study led to another phase II study involving pemetrexed
in the treatment of MBC patients pretreated with anthra-
cyclines.[54] In this study, 77 patients were treated with
pemetrexed 600 mg/m2, and the ORR was found to be
21%. Median duration of response was 5.5 months, and
median OS was 10.7 months. Again, high grade toxicities
included neutropenia and thrombocytopenia. Another
phase II study evaluated pemetrexed in heavily pretreated
MBC.[55] The patients involved in the study were previ-
ously treated with an anthracycline, a taxane and capecit-
abine for MBC. 80 patients were treated with pemetrexed
600 mg/m2, and the ORR was found to be 8% with stable
disease achieved in 36% of patients with a median OS of
8.2 months.
Another study explored the efficacy and toxicity of peme-
trexed treatment at two different doses.[56] The study was
a phase II randomized, double-blind study using a 600
mg/m2 and 900 mg/m2 doses of pemetrexed to treat
locally recurrent or MBC in the first-line setting. The ORR
was similar in the two groups with the low dose group
achieving an ORR of 17% and the high dose group achiev-
ing an ORR of 15.6%. The PFS was also similar in both
groups (4.2 months vs 4.1 months). Both arms exhibited
minimal toxicity. The study confirmed that both doses of
pemetrexed yielded similar response rates and toxicity
profiles.
Pemetrexed has also been evaluated in combination ther-
apy. In a phase II open label, multi-center study of peme-
trexed and carboplatin, 50 patients with locally advanced
or MBC were treated in the first-line setting with the com-
bination of pemetrexed 600 mg/m2 and carboplatin AUC
5.[57] The ORR was found to be 54% with a median
response duration of 11.1 months and a median time to
disease progression of 10.3 months. Toxicities were pre-
dominantly bone marrow suppression related. It was con-
cluded that the combination of pemetrexed plusJournal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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carboplatin was feasible and had promising activity in the
first-line setting for the treatment of MBC.
At ASCO 2008, pemetrexed was evaluated as first-line
therapy for advanced or MBC patients.[58] 37 patients
with advanced or MBC were treated with pemetrexed 600
mg/m2, and the results revealed an ORR of 26.5% with
47% of patients achieving stable disease. The median
duration of response was 6.5 months, and the median PFS
was 4.1 months. Median OS was 18.9 months. Again, tox-
icities were related to myelosuppression and anemia. The
study showed that pemetrexed achieved moderate activity
in the first-line setting with a tolerable toxicity profile
without alopecia.
Larotaxel
Larotaxel (XRP9881) is a novel taxoid with preclinical
activity against taxane-resistant breast cancer. It first
gained attention in a phase II study in patients with MBC
who previously received taxane-based therapy.[59] In this
study139 patients were stratified by response to prior tax-
ane therapy (resistant or non-resistant) and received laro-
taxel 90 mg/m2 monotherapy. In the non-resistant group,
the ORR was 42%, the median duration of response was
5.3 months, the median TTP was 5.4 months and the
median survival time was 22.6 months. In the resistant
group the ORR was 19%, the median duration of response
was 5 months, the median TTP was 1.6 months, and the
median survival time was 9.8 months. The most common
adverse events were neutropenia and fatigue. It was con-
cluded that larotaxel has activity in patients refractory to
taxane treatment with a tolerable safety profile.
At ASCO 2008, larotaxel was evaluated in combination
with trastuzumab in patients with HER2 positive
MBC.[60] The patients received larotaxel 90 mg/m2 and
trastuzumab 6 mg/kg every three weeks. The presentation
was an interim analysis of a phase II open label study in
HER2 positive MBC patients that included patients with
asymptomatic brain metastases. Out of 26 evaluable
patients, 11 patients (42.3%) achieved a PR, and the most
common adverse events were neutropenia, diarrhea, and
asthenia. This study suggests that the combination of tras-
tuzumab and larotaxel is feasible with good activity in
pretreated patients with high tumor burden including
brain metastases.
Ortataxel
Ortataxel is another novel new-generation taxane which
has shown activity in preclinical models in tumors resist-
ant to taxane therapy. At 2008 ASCO, a single-arm phase
II study was presented treating taxane-resistant MBC with
ortataxel 75 mg/m2.[61] Of the 76 evaluable patients, 7%
of patients achieved a PR while 38% achieved stable dis-
ease. The most common adverse events were neutropenia,
peripheral neuropathy, fatigue and malaise. It was con-
cluded that ortataxel continues to have activity in taxane-
resistant MBC patients and has a manageable toxicity pro-
file.
Future therapies
Several other agents continue to be investigated for the
treatment of breast cancer patients that appear to be
promising. One compound that was evaluated at ASCO
2008 was paclitaxel polyglumex which is a macromolecu-
lar conjugate of paclitaxel bound to poly-L-glutamic acid
which appears more attractive than traditional paclitaxel
in that it causes less alopecia, has a shorter infusion time,
requires no premedication, and has an enhanced tumor
permeability.[62] The agent was combined with capecit-
abine and used to treat MBC patients in a single stage
phase II study and was found to be tolerable and have
activity in MBC patients.
IMP321 is a novel immunomodulator derived from the
natural human protein LAG-3, a ligand for MHC class II
molecules which acts indirectly on T cell responses by
MHC class II APC activation.[63] It was evaluated in com-
bination with weekly paclitaxel in a phase I study in MBC
at ASCO 2008 and was found to be well tolerated when
given subcutaneously over 6 months.
BZL101 is an aqueous extract of the sutellaria barbata
herb which demonstrated in vitro growth inhibiting prop-
erties in breast cancer cell lines without affecting normal
breast cancer cells thus having a favorable toxicity profile.
It was evaluated at 2008 ASCO in a phase I open-label
study of heavily pretreated MBC patients receiving
BZL101 in a dose escalating fashion.[64] Of 5 patients
evaluable for response, one patient achieved stable dis-
ease for 8 months with radiographic evidence of tumor
shrinkage. The most common adverse events included
diarrhea, nausea, headache and ALT increase. It was con-
cluded that BZL101 has a favorable toxicity profile with
encouraging activity in heavily pretreated MBC patients.
Eribulin mesylate is a non-taxane microtubule dynamics
inhibitor which was evaluated at ASCO 2008 in a phase II
study in MBC patients previously treated with anthracy-
cline, taxane, and capecitabine therapy.[65] The single
arm, open label phase II study enrolled 291 patients, and
the results showed an ORR of 9.3% and a CBR of 17.1%
in this group of heavily pretreated patients.
Enzastaurin is a potent serine-threonine kinase inhibitor
which selectively targets PKCβ and PI3K/AKT signaling
pathways and was evaluated at ASCO 2008 in a phase II
study in MBC patients previously treated with an anthra-
cycline and a taxane containing regimen.[66] The mono-Journal of Hematology & Oncology 2008, 1:16 http://www.jhoonline.org/content/1/1/16
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therapy was well tolerated but it was found to have no
activity in this pretreated population of MBC patients.
PF-00299804 is an orally active pan-HER tyrosine kinase
inhibitor which specifically and irreversibly binds to and
inhibits HER1, HER2 and HER4 which was evaluated in
non-small cell lung cancer patients at ASCO 2008 but also
exhibits potential activity in HER2 positive breast cancer
patients.[67]
Motesanib is a small molecule tyrosine kinase inhibitor of
VEGF that targets VEGFR 1, 2, 3 and PDGF that has been
evaluated in preclinical models in combination with
either tamoxifen or docetaxel and was shown to have
potential use in breast cancer.[68] A large phase II clinical
trial is ongoing evaluating motesanib and paclitaxel in the
treatment of breast cancer).[47]
Vorinostat is a histone deacetylase inhibitor that is cur-
rently approved for treatment of cutaneous T-cell lym-
phoma but has also shown activity in other
malignancies.[69] It is currently being evaluated in the
treatment of MBC in combination therapy with multiple
agents including tamoxifen and capecitabine.[69]
GDC-0449 is a novel small molecule antagonist of the
hedgehog signaling pathway which is an important path-
way for tumor survival and growth implicated in multiple
solid organ tumors.[70] It was evaluated at ASCO 2008 in
a first in human, first in class phase I study in patients with
advanced solid tumors and hopes to be a promising agent
in the treatment of breast cancer.[71]
Conclusion
In recent years there have been significant advances in the
treatment of all types of cancer, but in particular breast
cancer. These accomplishments have been led by the
arrival of targeted therapies including hormonal inhibi-
tors, HER2 inhibitors and now inhibitors of several addi-
tional targets. Many of these agents are now incorporated
in the first-line treatment of several groups of MBC
patients and continue to be the foundation of successful
treatments. In addition, the manipulation of conven-
tional chemotherapeutic agents for a more pronounced
effect in MBC has been an exciting area in the treatment of
breast cancer.
With increasing tumor resistance to chemotherapy in
MBC, it is of vital importance to continue to apply these
novel therapies to current treatment standards and to con-
tinue to search for newer agents that are under investiga-
tion for use in breast cancer. The role of most of these
biologic and targeted agents is thus far undefined. The rel-
atively safe toxicity profile and convenience of these
agents often times makes them a more attractive option
when compared to conventional cytotoxic chemotherapy.
It is now imperative for researchers and clinicians to estab-
lish the efficacy and role of these novel agents in combi-
nation or as monotherapy in order to develop new
strategies in the treatment of breast cancer. By continuing
to evaluate these agents in clinical trials, investigators
hope to not only define their role in cancer therapeutics
but also stimulate a further influx of targeted therapies in
the future.
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